Phase 3 study for people with Macular Degeneration

Recruiting Phase 3

Sources: ClinicalTrials.gov Checked: 12 October 2026 Not medical advice

This trial at a glance

Status Recruiting
Phase Phase 3
Sponsor EyeBiotech Ltd.
Registry number NCT07440225
Started 27 March 2026 Today 16 October 2026 Estimated completion 30 June 2028

Where this trial is running

Trial sites and the status recorded for each
SiteCityState or countryStatus at this site
Eye Clinic Albury Wodonga (Site 425) Albury NSW Recruiting
Retina and Eye Consultants Hurstville NSW Recruiting
Retina and Macula Specialists Hurstville, Sydney NSW Recruiting
Launceston Eye Doctors Launceston TAS Recruiting
Nexus Eyecare Norwest NSW Recruiting
Marsden Eye Specialists (Site 420) Parramatta NSW Recruiting
Marsden Eye Specialists (Site 423) Strathfield NSW Recruiting
Sydney Eye Hospital (Site 426) Sydney NSW Recruiting
Sydney Retina Clinic and Day Surgery (Site 424) Sydney NSW Recruiting

voxsanity.com.au · trial sites from public registries · registry record synced 12 October 2026 · not medical advice

Who can join

Age 50 Years and over
Sex Anyone, regardless of sex
Healthy volunteers Not accepted
Enrolment target 960

The official eligibility criteria

Registry text, reproduced exactly. These are the words the trial's sponsor published on ClinicalTrials.gov. They have not been edited, shortened or rewritten, and they are written for researchers rather than for patients.

The main inclusion criteria include but are not limited to the following:

* Has treatment naive choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD) including subfoveal, juxtafoveal and extrafoveal lesions or retinal angiomatous proliferations (RAP) and polypoidal choroidal vascularization (PCV) lesions in at least one eye (study eye)

* The diagnosis of neovascular age-related macular degeneration (NVAMD) must have been made within 21 days prior to starting study treatment

The main exclusion criteria include but are not limited to the following

* Has uncontrolled blood pressure at screening

* History of any prior macular laser photocoagulation in the study eye

* History of uveitis in either eye

* History of cataract surgery, minimally invasive glaucoma surgery, or Yttrium-Aluminium Garnet (Yag) laser capsulotomy in the study eye within 90 days before entering the study

* Has uncontrolled glaucoma in the study eye

* Active retinal disease other than the condition under investigation in the study eye

* Has previously received anti- vascular endothelial growth factor (VEGF) therapy or other intravitreal (IVT) therapy in the study eye

Dates on the record

Started 27 March 2026
Estimated completion 30 June 2028
Registry last updated 2 October 2026
Checked by Voxsanity 12 October 2026

Results, publications and the official record

Sources and dates

  • ClinicalTrials.gov – the record this page reformats
  • ClinicalTrials.gov processing date: 2 October 2026.
  • This page last checked by Voxsanity: 12 October 2026.

Voxsanity reformats data from public registries into this layout. It does not edit, interpret or add to what the registry published.

Not medical advice.

Individual trial records are refreshed on a rolling basis rather than all at once, so a record may be up to several weeks old. Each trial page and trial card shows the date its own record was last synced. Where a record has lagged, its status, sites and enrolment can differ from the current registry state in either direction, so check the registry link on the trial page before acting on them.

Letter for your doctor

A one-page summary of this trial to print or email to your GP. It carries the registry's own record of the trial and its eligibility criteria, and nothing Voxsanity has written about whether it suits you.